Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MBF-118 in Healthy Volunteers
NCT05921916Phase 1Completed
- Sponsor
- Medibiofarma
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MBF-118 in cancer (9 arms), sponsored by Medibiofarma. Primary endpoint: Number of Adverse events. Started Jul 2020; status: completed.
02
Drugs
MBF-118
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05921916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921916.